ImmunologyArthritis Rheumatoid

Autoimmune Disease 2026: JAK Inhibitors Expand, EULAR Rewrites the Playbook

12 FDA-approved JAK inhibitors, updated EULAR guidelines, and the TYK2 era beginning

SR-2026-010

EditorMara Voss

CopywritersEditorial Team

Coming Soon

Autoimmune Disease 2026: JAK Inhibitors Expand, EULAR Rewrites the Playbook

12 FDA-approved JAK inhibitors, updated EULAR guidelines, and the TYK2 era beginning

Why We Are Covering This

The 12th JAK inhibitor was approved in July 2025 and EULAR updated RA recommendations are now driving formulary decisions at health systems worldwide. The safety-efficacy debate has moved from academic conferences to P&T committee tables.

What to Expect

You will be able to navigate the 12-drug JAK inhibitor landscape, apply the updated safety label comparisons to real formulary decisions, and understand where TYK2 inhibitors fit in the evolving autoimmune treatment hierarchy.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first

thelifesciencefeed.com · Special Report

SR-2026-01007/26

Hypersensitivity

Allergen Immunotherapy Modifies Disease Trajectory in Allergic Rhinitis

Allergen immunotherapy (AIT) demonstrates efficacy in reducing allergic rhinitis symptoms and preventing asthma development, offering disease modification.

Autoinflammatory Diseases

Autoimmune Drug Revoked Following New Safety Data

A treatment for a specific autoimmune condition has been withdrawn from the market due to emerging safety concerns identified in post-market surveillance.

Immune Drivers in Autoimmune Cytopenias Inform Patient Care

Immune Thrombocytopenia

EHA 2026

Immune Drivers in Autoimmune Cytopenias Inform Patient Care

Understanding immune drivers in autoimmune cytopenias, discussed at EHA 2026, offers insights into targeted therapies and improved patient management.

CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management

Autoinflammatory Diseases

EULAR 2026

CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management

Targeting CD19+ B-cells offers a corticosteroid-sparing strategy for IgG4-Related Disease, addressing relapse rates and long-term toxicity.

Autoimmune Disease 2026: JAK Inhibitors Expand, EULAR Rewrites the Playbook

Autoimmune Disease 2026: JAK Inhibitors Expand, EULAR Rewrites the Playbook

Be first when this report publishes

Related Articles